Deciphering β-lactamase-independent p-lactam resistance evolution trajectories in Pseudomonas aeruginosa

被引:34
作者
Cabot, Gabriel
Florit-Mendoza, Llorenc
Sanchez-Diener, Irina
Zamorano, Laura
Oliver, Antonio [1 ]
机构
[1] Hosp Univ Son Espases, Serv Microbiol, Inst Invest Sanitaria Illes Balea IdISBa, Palma De Mallorca, Spain
关键词
CYSTIC-FIBROSIS; ANTIMICROBIAL RESISTANCE; CEFTOLOZANE-TAZOBACTAM; GENETIC-DETERMINANTS; STRAINS; SUSCEPTIBILITY; INFECTIONS; ADAPTATION; SEQUENCE; DELETION;
D O I
10.1093/jac/dky364
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: While resistance related to the expression of beta-Eactamases, such as AmpC from Pseudomonas aeruginosa, has been deeply studied, this work addresses the gap in the knowledge of other potential bacterial strategies to overcome the activity of beta-lactams when beta-lactamases are not expressed. Methods: We analysed 13-lactam resistance evolution trajectories in a WT strain and in isogenic mutants either lacking AmpC (AmpC mutant) or unable to express it (AmpG mutant), exposed to increasing concentrations of ceftazidime for 7 days in quintuplicate experiments, Characterization of evolved lineages included susceptibility profiles, whole-genome sequences, resistance mechanisms, fitness (competitive growth assays) and virulence (Caenorhabditis elegans model). Results: Development of resistance was faster for the WT strain but, after 7 days, all strains reached clinical ceftazidime resistance levels, The main resistance mechanism in the WT strain was ampC overexpression, due to mutations in clacB and ampD or mpl, In contrast, ampC overexpression did not evolve in any of the AmpG lineages. Moreover, sequencing of the Delta AmpC and Delta AmpG evolved lineages revealed alternative resistance mutations (not seen in WT lineages) that included, in all cases, large (50-600 kb) deletions of specific chromosomal regions together with mutations leading to p-lactam target [ftsI (PBP3)] modification and/or the overexpression or structural modification of the efflux pump MexAB-OprM. Finally, evolved lineages from the AmpC and, especially, AmpG mutants showed a reduced fitness and virulence. Conclusions: In addition to providing new insights intop-lactam resistance mechanisms and evolution, our findings should be helpful for guiding future strategies to combat P. aeruginosa nfections.
引用
收藏
页码:3322 / 3331
页数:10
相关论文
共 38 条
  • [1] Genetic Determinants Involved in the Susceptibility of Pseudomonas aeruginosa to β-Lactam Antibiotics
    Alvarez-Ortega, Carolina
    Wiegand, Irith
    Olivares, Jorge
    Hancock, Robert E. W.
    Luis Martinez, Jose
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4159 - 4167
  • [2] Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung
    Caballero, Julio Diaz
    Clark, Shawn T.
    Coburn, Bryan
    Zhang, Yu
    Wang, Pauline W.
    Donaldson, Sylva L.
    Tullis, D. Elizabeth
    Yau, Yvonne C. W.
    Waters, Valerie J.
    Hwang, David M.
    Guttman, David S.
    [J]. MBIO, 2015, 6 (05):
  • [3] Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
    Cabot, Gabriel
    Lopez-Causape, Carla
    Ocampo-Sosa, Alain A.
    Sommer, Lea M.
    Angeles Dominguez, Maria
    Zamorano, Laura
    Juan, Carlos
    Tubau, Fe
    Rodriguez, Cristina
    Moya, Bartolome
    Pena, Carmen
    Martinez-Martinez, Luis
    Plesiat, Patrick
    Oliver, Antonio
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (12) : 7415 - 7423
  • [4] Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates
    Cabot, Gabriel
    Zamorano, Laura
    Moya, Bartolome
    Juan, Carlos
    Navas, Alfonso
    Blazquez, Jesus
    Oliver, Antonio
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1767 - 1778
  • [5] Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
    Cabot, Gabriel
    Bruchmann, Sebastian
    Mulet, Xavier
    Zamorano, Laura
    Moya, Bartolome
    Juan, Carlos
    Haussler, Susanne
    Oliver, Antonio
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) : 3091 - 3099
  • [6] Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study
    Cabot, Gabriel
    Ocampo-Sosa, Alain A.
    Tubau, Fe
    Macia, Maria D.
    Rodriguez, Cristina
    Moya, Bartolome
    Zamorano, Laura
    Suarez, Cristina
    Pena, Carmen
    Martinez-Martinez, Luis
    Oliver, Antonio
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) : 1906 - 1911
  • [7] Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic
    Chalhoub, Hussein
    Pletzer, Daniel
    Weingart, Helge
    Braun, Yvonne
    Tunney, Michael M.
    Elborn, J. Stuart
    Rodriguez-Villalobos, Hector
    Plesiat, Patrick
    Kahl, Barbara C.
    Denis, Olivier
    Winterhalter, Mathias
    Tulkens, Paul M.
    Van Bambeke, Francoise
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [8] Del Barrio-Tofino E, 2017, ANTIMICROB AGENTS CH, V61
  • [9] Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease
    Doering, Gerd
    Parameswaran, Iyer G.
    Murphy, Timothy F.
    [J]. FEMS MICROBIOLOGY REVIEWS, 2011, 35 (01) : 124 - 146
  • [10] Genomewide Identification of Genetic Determinants of Antimicrobial Drug Resistance in Pseudomonas aeruginosa
    Doetsch, Andreas
    Becker, Tanja
    Pommerenke, Claudia
    Magnowska, Zofia
    Jaensch, Lothar
    Haeussler, Susanne
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (06) : 2522 - 2531